<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00475956</url>
  </required_header>
  <id_info>
    <org_study_id>D8480C00014</org_study_id>
    <secondary_id>EuDract #2006-003505-55</secondary_id>
    <nct_id>NCT00475956</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours</brief_title>
  <official_title>Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in
      combination with AZD0530, in treating patients with advanced solid tumours are safe,
      tolerable and efficacious.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and tolerability of ascending daily oral doses of AZD2171 when co-administered with AZD0530 to patients with advanced solid tumours by assessment of AEs, vital signs, HRCT Scans, clin chem, haematology, urinalysis, ECG and phys exam</measure>
    <time_frame>assessed at each visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of AZD2171 alone and in combination with AZD0530</measure>
    <time_frame>assessed at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and efficacy</measure>
    <time_frame>assessed at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic variation of pathways targeted by AZD2171 and AZD0530</measure>
    <time_frame>assessed during study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2171 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2171 + AZD0530</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2171</intervention_name>
    <description>oral tablet multiple ascending doses 20, 30 or 45 mg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>cediranib</other_name>
    <other_name>RECENTIN™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0530</intervention_name>
    <description>oral tablet multiple ascending doses 125 mg or 175 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written consent

          -  Cancer diagnosis &amp; stage

          -  Patients for whom no standard therapy exists

          -  World Health Organization (WHO) performance status 0-2

          -  One or more measurable lesions

        Exclusion Criteria:

          -  Prostate cancer

          -  Untreated unstable brain or meningeal metastases

          -  Specific laboratory ranges

          -  Pregnant or breast-feeding women

          -  Any evidence of severe or uncontrolled diseases

          -  Participation in other trials within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Roberston</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanja Trarbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinikum der GHS Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wurttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <state>Ruhr</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herne</city>
        <state>Ruhr</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>April 14, 2010</last_update_submitted>
  <last_update_submitted_qc>April 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jane Robertson, MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Tumour</keyword>
  <keyword>Advanced Solid Tumour</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Choriocarcinoma</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Peritoneal Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cediranib</mesh_term>
    <mesh_term>Saracatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

